Drugs / Tozadenant
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03200080 | Sep → Nov 2017 | substance abuse | Biotie Therapies Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03212313 | Jun → Dec 2017 | — | Biotie Therapies Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02240290 | Sep → Oct 2013 | — | Biotie Therapies Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00605553 | Apr 2008 → May 2009 | Parkinson disease | Biotie Therapies Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT01283594 | Mar 2011 → Oct 2012 | Parkinson disease | Biotie Therapies Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT03051607 | Apr 2017 → Jan 2018 | Parkinson disease | Biotie Therapies Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02453386 | Jul 2015 → Jan 2018 | Parkinson disease | Biotie Therapies Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT00783276 Comparator | Oct 2008 → Jan 2013 | cocaine dependence | Virginia Commonwealth University | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tozadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00605553 ↗ |
| Known as | A-2A (3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105747 ↗ |
| Known as | RO-4494351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105747 ↗ |
| Known as | RO-4494351-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105747 ↗ |
| Known as | RO-4494351-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105747 ↗ |
| Known as | SYN115 | “Tozadenant (SYN115) is an oral, selective adenosine A2A receptor antagonist that improves motor function in animal models of Parkinson's disease.” PMID 25008546 ↗ Jul 2014 |
| Action | Inhibit | “Adenosine A2a receptor antagonist” CHEMBL2105747 ↗1“adenosine A(2a) antagonist” PMID 21123574 ↗ Dec 2010 |
| Modality | Small molecule | — CHEMBL2105747 ↗ |
| Route | Oral | “Tozadenant 20 mg oral capsules” NCT00605553 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL2105747 ↗ |